KR20090086806A - 초고압을 이용한 인삼 추출물의 제조방법 - Google Patents
초고압을 이용한 인삼 추출물의 제조방법 Download PDFInfo
- Publication number
- KR20090086806A KR20090086806A KR1020080012278A KR20080012278A KR20090086806A KR 20090086806 A KR20090086806 A KR 20090086806A KR 1020080012278 A KR1020080012278 A KR 1020080012278A KR 20080012278 A KR20080012278 A KR 20080012278A KR 20090086806 A KR20090086806 A KR 20090086806A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- mpa
- ginsenoside
- pressure
- content
- Prior art date
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 60
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 60
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 60
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 title description 12
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 64
- 108090000790 Enzymes Proteins 0.000 claims abstract description 54
- 102000004190 Enzymes Human genes 0.000 claims abstract description 54
- 229940088598 enzyme Drugs 0.000 claims abstract description 54
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 38
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 33
- 108010059820 Polygalacturonase Proteins 0.000 claims abstract description 33
- 108010093305 exopolygalacturonase Proteins 0.000 claims abstract description 33
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 229920002678 cellulose Polymers 0.000 claims abstract description 14
- 239000001913 cellulose Substances 0.000 claims abstract description 14
- 101710130006 Beta-glucanase Proteins 0.000 claims abstract description 12
- 229940059442 hemicellulase Drugs 0.000 claims abstract description 12
- 108010002430 hemicellulase Proteins 0.000 claims abstract description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 11
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract description 11
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 29
- 108010059892 Cellulase Proteins 0.000 claims description 13
- 229940106157 cellulase Drugs 0.000 claims description 13
- 229920002488 Hemicellulose Polymers 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 abstract description 24
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract description 5
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 52
- 235000000346 sugar Nutrition 0.000 description 27
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 19
- 229930182490 saponin Natural products 0.000 description 11
- 150000007949 saponins Chemical class 0.000 description 11
- 235000017709 saponins Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000003301 hydrolyzing effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 5
- -1 Rg2 Chemical compound 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- AQFATCCHOXBYNK-UHFFFAOYSA-N 2-piperidin-1-ium-1-ylethyl 1-cyclohexylcyclohexane-1-carboxylate;chloride Chemical compound [Cl-].C1CCCCC1(C1CCCCC1)C(=O)OCC[NH+]1CCCCC1 AQFATCCHOXBYNK-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000004072 triols Chemical group 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/46—Ultra high pressure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
시료 | 압력 | 총당 (Total sugar) (mg/ml) | 산성당 (Uronic acid) (㎍/ml) | 폴리페놀 (Polyphenols) (㎍/ml) | Dry weight (%) |
비교예1 | 0(control) | 103.2±14.2a | 239.4±37.9b | 346.3±7.8d | 9.1±0.2 a |
실시예1 | 30 MPa | 113.1±10.7a | 302.0±113.7ab | 431.3±17.1a | 8.2±0.2b |
실시예2 | 50 MPa | 81.2±4.3b | 185.9±38.1b | 422.4±12.4a | 6.3±0.2d |
실시예3 | 80 MPa | 93.6±19.0ab | 69.7±15.2c | 398.1±8.6ab | 6.3±0.05e |
실시예4 | 100 MPa | 76.7±27.9b | 418.8±42.4a | 361.8±5.3c | 7.6±0.07c |
기기들 | SP930D Solvent delivery pump SDV50A Vacuum degasser and valve module CTS 30 Column oven (Young-Lin Co. Ltd., Korea) |
검출기 | ELSD (GmbH, Germany) |
컬럼 | Prevail Carbohydrate ES 5u, 250×4.6 mm (Alltech, USA) |
오븐 온도 | 35℃ |
용매 | A (Acetonitrile : Water : IPA = 80 : 5 : 15) B (Acetonitrile : Water : IPA = 67 : 21 : 12) |
주입 부피 | 20 ㎕ |
Time (min) | Flow (ml/min) | %A | %B |
초기(Initial) | 0.8 | 90 | 10 |
28 | 0.8 | 15 | 85 |
35 | 0.8 | 20 | 80 |
45 | 0.8 | 25 | 75 |
50 | 0.8 | 10 | 90 |
51 | 0.8 | 0 | 100 |
57 | 0.8 | 75 | 25 |
58 | 0.8 | 90 | 10 |
65 | 0.8 | 90 | 10 |
진세노사이드 | concentration (㎍/mL) | ||||
비교예1 (0 MPa) | 실시예 1 (30 MPa) | 실시예 2 (50 MPa) | 실시예 3 (80 MPa) | 실시예4 (100 MPa) | |
컴파운드 K | 0 | 0.00 | 0.00 | 0.00 | 0 |
Rh2 | 0 | 0.00 | 0.00 | 0.00 | 0 |
Rh1 | 0 | 0.00 | 0.00 | 0.00 | 0 |
Rg5+RK1 | 0 | 0.00 | 0.00 | 0.00 | 0 |
Rg2 | 228.9 | 228.3 | 228.1 | 240.6 | 246.9 |
Rg3 | 0 | 0.00 | 0.00 | 0.00 | 0 |
Rg1 | 787.5 | 768.0 | 805.5 | 844.9 | 916.9 |
Rf | 359.9 | 388.4 | 413.1 | 421.3 | 431.1 |
Re | 2924.7 | 2909.3 | 2917.7 | 3475.9 | 2130.1 |
Rd | 2453.7 | 2437.1 | 2820.5 | 2868.8 | 1499.5 |
Rb2 | 1275.8 | 1486.6 | 1689.6 | 2605.9 | 1558.7 |
Rc | 3739.9 | 3388.9 | 3854.6 | 4787.0 | 2834.2 |
Rb1 | 5284.3 | 5550.1 | 6357.0 | 7831.1 | 5908.1 |
total | 17054.7 | 17156.7 | 19086.1 | 23075.5 | 15255.5 |
효소 | 주요 활성 | 공급원 | 최적 조건 | |
pH | 온도(℃) | |||
Ultraflo L (Novozymes, Dittingen, Switzerland) | 베타-글루카네 이즈 | 휴미콜라 인솔렌즈(H umicola insolens) | 6 | 40 |
Rapidase (DSM, Delft, Netherlands) | 펙티네이즈, 헤미셀룰레이즈, 셀룰레이즈 | 아스프 니거(Asp. Niger) & 티.롱기브라키아툼(T.longibrachiatum) | 4.0-5.0 | 10-55 |
Viscozyme (Novozymes, Dittingen, Switzerland) | 아라비네이즈, 셀룰레이즈, 글루카네이즈, 헤미셀룰레이즈, 자일라네이즈 | 아스프.(Asp.) 속 | 3.3-5.5 | 40-50 |
Cytolase PCL 5 (Gist-Brocades, Seclin, France) | 펙티네이즈 | 아스프. 니거(Asp. Niger) | 2.5-5.0 | 10-55 |
Econase CE (AB Enzymes GmbH, Darmstadt, Germany) | 셀룰레이즈 | 트리코더마 (Trichoder ma) 속 | 4.0-5.5 | 55 |
압력 효소 | 30MPa | 50MPa | 80MPa | 100MPa |
control(무효소) | 비교예2 | 비교예3 | 비교예4 | 비교예5 |
Ultraflo L | 실시예5 | 실시예10 | 실시예15 | 실시예20 |
Rapidase | 실시예6 | 실시예11 | 실시예16 | 실시예21 |
Viscozyme | 실시예7 | 실시예12 | 실시예17 | 실시예22 |
Cytolase PCL 5 | 실시예8 | 실시예13 | 실시예18 | 실시예23 |
Econase CE | 실시예9 | 실시예14 | 실시예19 | 실시예24 |
총 당(Total sugar) (mg/ml) | ||||
효소 | 30 MPa | 50 MPa | 80 MPa | 100 Mpa |
control | 비교예2 113.1±10.7bc | 비교예3 81.2±4.3a | 비교예4 93.6±19.0ab | 비교예5 76.7±27.9d |
Ultraflo L | 실시예5 148.8±21.1d | 실시예10 91.0±11.8ab | 실시예15 71.9±7.5a | 실시예20 118.4±19.1cd |
Rapidase | 실시예6 197.6±5.6fg | 실시예11 146.5±9.0d | 실시예16 161.0±19.0de | 실시예21 169.6±25.4ab |
Viscozyme | 실시예7 155.7±11.1de | 실시예12 179.3±24.5ef | 실시예17 188.6±16.2fg | 실시예22 197.0±38.0a |
Cytolase PCL 5 | 실시예8 187.9±20.8fg | 실시예13 157.9±12.2de | 실시예18 214.6±21.0g | 실시예23 141.0±25.2bc |
Econase CE | 실시예9 137.9±23.2cd | 실시예14 100.0±6.8ab | 실시예19 135.3±6.1cd | 실시예24 126.0±4.03bc |
산성당(Uronic acid) (㎍/ml) | ||||
효소 | 30 MPa | 50 MPa | 80 MPa | 100 MPa |
control | 비교예2 302.0±113.7abc | 비교예3 185.9±38.1ab | 비교예4 69.7±15.2ab | 비교예5 418.8±42.4b |
Ultraflo L | 실시예5 130.3±30.3ab | 실시예10 120.2±97.4ab | 실시예15 29.3±8.8a | 실시예20 320.8±194.2b |
Rapidase | 실시예6 1211.1±162.0gh | 실시예11 741.4±114.7ef | 실시예16 877.8±83.5ef | 실시예21 365.9±25.0b |
Viscozyme | 실시예7 600.00±84.4cde | 실시예12 1377.8±38.1hi | 실시예17 1266.7±347.26hi | 실시예22 1136.5±104.6a |
Cytolase PCL 5 | 실시예8 630.3±367.7def | 실시예13 731.3±263.5ef | 실시예18 1529.3±86.2i | 실시예23 546.7±120.9b |
Econase CE | 실시예9 867.7±46.3ef | 실시예14 362.6±126.2bcd | 실시예19 943.4±319.4fg | 실시예24 528.6±98.7b |
폴리페놀(polyphenols) (㎍/ml) | ||||
30 MPa | 50 MPa | 80 MPa | 100 MPa | |
control | 비교예2 431.3±17.1b | 비교예3 422.4±12.4b | 비교예4 398.1±8.6ab | 비교예5 361.8±5.3d |
Ultraflo L | 실시예5 502.5±25.0c | 실시예10 503.2±16.4c | 실시예15 372.0±28.9a | 실시예20 378.7±8.4cd |
Rapidase | 실시예6 702.7±27.1gh | 실시예11 708.0±25.2h | 실시예16 709.4±41.9h | 실시예21 544.8±24.4a |
Viscozyme | 실시예7 651.2±35.2ef | 실시예12 849.0±10.1j | 실시예17 874.4±40.6j | 실시예22 579.0±39.3a |
Cytolase PCL 5 | 실시예8 662.5±24.7fg | 실시예13 750.3±18.2i | 실시예18 785.5±12.3i | 실시예23 419.0±23.8c |
Econase CE | 실시예9 583.9±14.5d | 실시예14 613.5±3.7de | 실시예19 664.6±29.8fg | 실시예24 475.3±22.0b |
건물량(dry weight)(%) | ||||
30 MPa | 50 MPa | 80 MPa | 100 MPa | |
control | 비교예2 8.2±0.2d | 비교예3 6.3±0.2b | 비교예4 6.3±0.1b | 비교예5 7.6±0.07f |
Ultraflo L | 실시예5 8.9±0.2ef | 실시예10 7.2±0.1c | 실시예15 5.2±0.1a | 실시예20 8.6±0.08e |
Rapidase | 실시예6 12.3±0.2l | 실시예11 8.8±0.4ef | 실시예16 8.7±0.1e | 실시예21 10.7±0.1b |
Viscozyme | 실시예7 9.6±0.1g | 실시예12 10.6±0.1i | 실시예17 10.9±0.2jk | 실시예22 11.1±0.08a |
Cytolase PCL 5 | 실시예8 10.7±0.2ij | 실시예13 10.1±0.1h | 실시예18 11.2±0.5k | 실시예23 10.5±0.06c |
Econase CE | 실시예9 9.6±0.1g | 실시예14 7.9±0.1d | 실시예19 9.0±0.1f | 실시예24 9.2±0.04d |
진세노사이드 | 30 MPa (㎍/mL) | |||||
비교예2 (control) | 실시예5 (Ultraflo L) | 실시예6 (Rapidase) | 실시예7 (Viscozyme) | 실시예8 (Cytolase) | 실시예9 (Econase) | |
컴파운드 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg5+RK1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg2 | 228.3 | 256.4 | 308.3 | 0.0 | 378.5 | 254.0 |
Rg3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg1 | 768.0 | 1061.0 | 1275.6 | 854.4 | 1340.3 | 835.5 |
Rf | 388.4 | 616.2 | 621.7 | 412.1 | 508.2 | 457.4 |
Re | 2909.3 | 3869.4 | 4112.3 | 3209.9 | 2880.0 | 3236.3 |
Rd | 2437.1 | 4482.5 | 6958.2 | 2593. 9 | 8070.6 | 3928.3 |
Rb2 | 1486.6 | 2348.9 | 3013.4 | 1662.7 | 2286.4 | 1948.5 |
Rc | 3388.9 | 5295.0 | 3671.6 | 4388.0 | 1812.6 | 3948.4 |
Rb1 | 5550.1 | 7217.5 | 10914.3 | 6421.7 | 6927.9 | 6573.9 |
진세노사이드 | 50 Mpa (㎍/mL) | |||||
비교예3 (control) | 실시예10 (Ultraflo L) | 실시예11 (Rapidase) | 실시예12 (Viscozyme) | 실시예13 (Cytolase) | 실시예14 (Econase) | |
Compd K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg5+RK1 | 0.0 | 0.0 | 0.0 | 172.3 | 193.3 | 132.0 |
Rg2 | 228.1 | 242.6 | 208.9 | 209.7 | 204.96 | 197.3 |
Rg3 | 0.0 | 0.0 | 940.7 | 943.5 | 804.6 | 711.9 |
Rg1 | 805.5 | 869.3 | 296.1 | 312.8 | 246.8 | 279.0 |
Rf | 413.1 | 419.8 | 261.3 | 212.9 | 207.0 | 189.5 |
Re | 2917.7 | 3117.7 | 3151.8 | 3546.9 | 2091.3 | 2988.5 |
Rd | 2820.5 | 3628.2 | 5455.8 | 3574.6 | 5386.0 | 3678.7 |
Rb2 | 1689.6 | 2101.4 | 2173.3 | 2129.8 | 1710.8 | 2017.0 |
Rc | 3854.6 | 4514.9 | 2934.3 | 4388.2 | 1530.0 | 4342.3 |
Rb1 | 6357.0 | 7075.2 | 8281.0 | 9227.6 | 5685.5 | 7733.4 |
분획 | 80 Mpa (㎍/mL) | |||||
비교예4 (control) | 실시예15 (Ultraflo L) | 실시예16 (Rapidase) | 실시예17 (Viscozyme) | 실시예18 (Cytolase) | 실시예19 (Econase) | |
Compd K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg5+RK1 | 0.0 | 88.6 | 198.5 | 223.1 | 42.5 | 222.7 |
Rg2 | 240.6 | 196.6 | 205.1 | 216.2 | 0.0 | 211.8 |
Rg3 | 0.0 | 507.3 | 963.2 | 1131.9 | 985.8 | 1026.4 |
Rg1 | 844.9 | 251.3 | 324.2 | 362.5 | 175.7 | 365.6 |
Rf | 421.3 | 172.9 | 269.4 | 227.5 | 206.3 | 177.0 |
Re | 3475.9 | 2107.5 | 3113.5 | 4418.8 | 2859.9 | 4367.3 |
Rd | 2868.8 | 2718.0 | 5840.0 | 4650.9 | 7891.8 | 5574.2 |
Rb2 | 2605.9 | 1516.5 | 2185.7 | 2585.2 | 2548.0 | 2857.99 |
Rc | 4787.0 | 2967.9 | 2876.3 | 5405.6 | 1942.8 | 6187.5 |
Rb1 | 7831.1 | 3952.4 | 8089.3 | 10706.8 | 8374.8 | 10372.1 |
분획 | 농도 (㎍/mL) | |||||
비교예5 control | 실시예20 Ultraflo L | 실시예21 Rapidase | 실시예22 Viscozyme | 실시예23 Cytolase PCL 5 | 실시예24 Econitase CE | |
Rh2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rh1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Rg2 | 246.9 | 317.0 | 277.9 | 325.1 | 438.6 | 306.5 |
Rg3 | 0.0 | 110.4 | 0.0 | 109.2 | 107.7 | 110.0 |
Rg1 | 916.9 | 1334.6 | 1106.3 | 1326.9 | 1535.5 | 1225.5 |
Rf | 431.1 | 783.5 | 515.2 | 659.8 | 655.3 | 752.2 |
Re | 2130.1 | 3711.9 | 2514.7 | 3583.5 | 3895.0 | 2973.2 |
Rd | 1499.5 | 4292.4 | 3843.7 | 3571.5 | 6147.4 | 2750.3 |
Rc | 2834.2 | 5568.6 | 3210.6 | 4598.0 | 6082.2 | 4637.6 |
Rb2 | 1558.7 | 3025.0 | 1760.5 | 2504.5 | 4144.0 | 2525.8 |
Rb1 | 5908.1 | 9042.7 | 6485.7 | 9407.9 | 17948.0 | 8376.9 |
Claims (15)
- 20 내지 110MPa의 압력 하에서 인삼으로부터 진세노사이드를 추출하는 것을 포함하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제1항에 있어서, 상기 인삼은 홍삼인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제1항에 있어서, 상기 추출 전 또는 추출과 동시에 베타-글루카네이즈(β-glucanase), 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase), 셀룰레이즈(cellulase), 아라비네이즈(arabinase) 및 자일라네이즈(xylanase)로 구성된 군으로부터 선택된 하나 이상의 효소를 가하여 인삼을 가수분해시키는 것을 포함하는 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제3항에 있어서, 상기 진세노사이드는 Rg1이며, 상기 효소는 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase) 및 셀룰레이즈(cellulase)로 이루어진 군으로부터 선택된 하나 이상의 효소인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제4항에 있어서, 상기 효소는 펙티네이즈이며 상기 압력은 20 내지 40MPa인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제4항에 있어서, 상기 효소는 펙티네이즈이며 상기 압력은 90 내지 110MPa인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제3항에 있어서, 상기 진세노사이드는 Rg3이며, 상기 효소는 베타-글루카네이즈(β-glucanase), 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase) 및 셀룰레이즈(cellulase)로 이루어진 군으로부터 선택된 하나 이상의 효소인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제7항에 있어서, 상기 압력은 40 내지 90MPa인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제8항에 있어서, 상기 압력은 70 내지 90MPa이며, 상기 효소는 셀룰레이즈인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제3항에 있어서, 상기 진세노사이드는 Rg2이며, 상기 효소는 펙티네이즈이며, 상기 압력은 90 내지 110MPa인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제3항에 있어서, 상기 진세노사이드는 Rb1이며, 상기 압력은 20 내지 40MPa이며, 상기 효소는 펙티네이즈, 헤미셀룰레이즈 및 셀룰레이즈의 조합인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제3항에 있어서, 상기 진세노사이드는 Rb1이며, 상기 압력은 90 내지 110MPa이며, 상기 효소는 펙티네이즈인 것을 특징으로 하는 초고압을 이용한 인삼 추출물의 제조방법.
- 제1항 내지 제12항 중 어느 한 항에 따라 제조된 인삼 추출물을 유효성분으로 포함하는 건강식품 조성물.
- 제13항에 있어서, 상기 건강식품 조성물은, 감마 사이클로덱스트린을 더 포함하는 것을 특징으로 하는 건강식품 조성물.
- 제14항에 있어서, 상기 감마 사이클로덱스트린은 액상인 인삼 추출물이 100일 때 5 내지 20 중량부의 함량으로 함유된 것을 특징으로 하는 건강식품 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080012278A KR100970455B1 (ko) | 2008-02-11 | 2008-02-11 | 초고압을 이용한 인삼 추출물의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080012278A KR100970455B1 (ko) | 2008-02-11 | 2008-02-11 | 초고압을 이용한 인삼 추출물의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090086806A true KR20090086806A (ko) | 2009-08-14 |
KR100970455B1 KR100970455B1 (ko) | 2010-07-16 |
Family
ID=41206031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080012278A KR100970455B1 (ko) | 2008-02-11 | 2008-02-11 | 초고압을 이용한 인삼 추출물의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100970455B1 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101065956B1 (ko) * | 2008-12-16 | 2011-09-19 | 주식회사 동원에프앤비 | 효소 및 초고압을 이용한 홍삼제조방법 |
KR101328413B1 (ko) * | 2011-09-09 | 2013-11-14 | 주식회사 이노웨이 | 고압/효소분해에 의한 인삼류 유용성분의 추출방법 |
KR101360961B1 (ko) * | 2012-01-30 | 2014-02-12 | 전주대학교 산학협력단 | 홍삼자염의 제조방법 |
KR101397145B1 (ko) * | 2014-02-26 | 2014-05-19 | 양양군 | 산양산삼 추출 액상과 산양산삼을 동시에 얻는 방법 |
KR101412682B1 (ko) * | 2013-04-26 | 2014-08-14 | 주식회사 엔씨 | 수제홍삼 추출액의 제조방법 |
CN108185429A (zh) * | 2017-05-20 | 2018-06-22 | 郑毅男 | 一种利用超高压设备提取鲜人参的方法及其在健康食品中的用途 |
KR20190065788A (ko) * | 2017-12-04 | 2019-06-12 | 서울대학교산학협력단 | 인삼류로부터 진세노사이드를 고효율로 추출하는 방법 및 이에 의하여 추출된 진세노사이드 |
KR102322628B1 (ko) * | 2021-02-26 | 2021-11-04 | 이유정 | 특정 진세노사이드의 함량이 증대된 산삼배양근 추출물의 제조방법 및 진세노사이드 복합물을 이용한 탈모증상완화 및 육모촉진용 화장료 조성물 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101591251B1 (ko) * | 2013-09-26 | 2016-02-03 | 샘표식품 주식회사 | 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법 |
KR20230029011A (ko) | 2021-08-23 | 2023-03-03 | 주식회사 한빛향료 | 초고압처리를 이용하여 제조된 홍삼박 또는 흑삼박으로부터 고온고압수를 이용하여 산성다당체를 추출하는 방법 및 그 추출물 |
KR102665525B1 (ko) | 2021-08-23 | 2024-05-13 | 주식회사 한빛향료 | 초고압처리를 이용하여 제조된 홍삼 또는 흑삼으로부터 고온고압수를 이용하여 진세노사이드를 추출하는 방법 및 그 추출물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100378518B1 (ko) * | 2001-05-15 | 2003-04-03 | (주)수진바이오텍 | 홍삼 유효성분의 저분자화 방법 |
KR100445184B1 (ko) * | 2002-05-08 | 2004-08-21 | 주식회사 그린바이오텍 | 초고압을 이용한 신규한 인삼가공 방법 |
KR101066676B1 (ko) * | 2005-05-20 | 2011-09-21 | (주)아모레퍼시픽 | 경구용 피부 미용 개선용 조성물 |
-
2008
- 2008-02-11 KR KR1020080012278A patent/KR100970455B1/ko active IP Right Grant
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101065956B1 (ko) * | 2008-12-16 | 2011-09-19 | 주식회사 동원에프앤비 | 효소 및 초고압을 이용한 홍삼제조방법 |
KR101328413B1 (ko) * | 2011-09-09 | 2013-11-14 | 주식회사 이노웨이 | 고압/효소분해에 의한 인삼류 유용성분의 추출방법 |
KR101360961B1 (ko) * | 2012-01-30 | 2014-02-12 | 전주대학교 산학협력단 | 홍삼자염의 제조방법 |
KR101412682B1 (ko) * | 2013-04-26 | 2014-08-14 | 주식회사 엔씨 | 수제홍삼 추출액의 제조방법 |
KR101397145B1 (ko) * | 2014-02-26 | 2014-05-19 | 양양군 | 산양산삼 추출 액상과 산양산삼을 동시에 얻는 방법 |
CN108185429A (zh) * | 2017-05-20 | 2018-06-22 | 郑毅男 | 一种利用超高压设备提取鲜人参的方法及其在健康食品中的用途 |
KR20190065788A (ko) * | 2017-12-04 | 2019-06-12 | 서울대학교산학협력단 | 인삼류로부터 진세노사이드를 고효율로 추출하는 방법 및 이에 의하여 추출된 진세노사이드 |
KR102322628B1 (ko) * | 2021-02-26 | 2021-11-04 | 이유정 | 특정 진세노사이드의 함량이 증대된 산삼배양근 추출물의 제조방법 및 진세노사이드 복합물을 이용한 탈모증상완화 및 육모촉진용 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR100970455B1 (ko) | 2010-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100970455B1 (ko) | 초고압을 이용한 인삼 추출물의 제조방법 | |
KR100479803B1 (ko) | 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물 | |
JP5528718B2 (ja) | βグルカン組成物を用いた血糖値上昇抑制剤及びインスリン分泌促進剤 | |
JP4777776B2 (ja) | 酢を利用した人参製剤及びこれの製造方法 | |
KR102478724B1 (ko) | 감귤 발효 콤부차를 유효성분으로 포함하는 당뇨 또는 심혈관질환 치료용 조성물 | |
CN103977409A (zh) | 一种膳食补充剂组合物及其用于调控血糖的方法 | |
KR100949247B1 (ko) | 가공 인삼 또는 가공 인삼 추출물의 제조방법 | |
KR20060000488A (ko) | 인삼 또는 홍삼 추출물, 그의 유산균 발효물 및 그의장내세균 발효물로 이루어진 군으로부터 선택된 1종이상의 인삼 추출물 소양증 예방 및 치료제 조성물 | |
KR20100018018A (ko) | 가공 인삼 또는 가공 인삼 추출물의 제조방법 | |
KR101750779B1 (ko) | 아글리콘인 ppd 및/또는 ppt를 유효성분으로 포함하는 항피로용 조성물 | |
CN110859869A (zh) | 一种预防和治疗心脑血管疾病的组合物及其制备方法 | |
KR100848686B1 (ko) | 유산균으로 감마-아미노부틸산과 생물전환 사포닌을 동시에강화한 발효 인삼 조성물 | |
KR101530982B1 (ko) | 감귤류 가공부산물 유래의 면역활성다당 및 비배당체 플라보노이드의 제조방법 | |
KR20110093477A (ko) | 발효 홍삼을 포함하는 항암 조성물 | |
KR20200094435A (ko) | 비배당체 함량이 증가된 감국 효소처리 추출물의 제조방법 및 이로 제조된 비만 예방 또는 치료용 조성물 | |
KR20040099670A (ko) | 유효 성분으로 진세노시드 Rh2를 함유하는 뇌세포 보호조성물 | |
KR100759772B1 (ko) | 유효 성분으로 진세노시드 Rh2를 함유하는 뇌세포 보호조성물 | |
KR101975018B1 (ko) | 인삼열매-목이버섯 균사체 혼합 배양물을 포함하는 콜레스테롤 저하용 조성물 | |
JP2010059105A (ja) | 炎症性腸疾患の予防又は治療剤 | |
KR101787082B1 (ko) | 유효 사포닌 함량이 증가된 도라지 추출물을 유효성분으로 함유하는 류마티스 관절염 치료용 약학적 조성물 | |
US20240123019A1 (en) | Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract | |
KR101620160B1 (ko) | 백출 속 및 탱자를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 | |
CN111454993B (zh) | 一种决明子发酵物及其应用 | |
KR102444884B1 (ko) | 비타민 b1 및 b2를 고함량으로 함유하는 맥주효모 추출물 및 이의 제조방법 | |
KR101935200B1 (ko) | 패에서 분리한 신규 화합물 헥사데카플로레톨 및 그 화합물을 이용한 항당뇨 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130708 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140708 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150708 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160708 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170710 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180709 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190708 Year of fee payment: 10 |